Bristol-Myers Squibb, Celgene slide following news of delayed deal and psoriasis drug divestmentCNBC • 06/24/19
Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces SetbackBenzinga • 06/24/19
Bristol-Myers Plans To Divest Celgene Blockbuster To Satisfy RegulatorsInvestors Business Daily • 06/24/19
Bristol-Myers offers update on liver cancer trial, to sell Otzela to hasten close of Celgene dealMarket Watch • 06/24/19
What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?The Motley Fool • 06/20/19
Bristol-Myers (BMY) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 06/19/19
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to ProfitThe Motley Fool • 06/12/19
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster HeadacheZacks Investment Research • 06/07/19